07 June 2018
The Russian pharmaceutical company NovaMedica (RUSNANO's portfolio company) has registered a unique drug Fissario® for proctologic diseases treatment, based on a new mechanism of action not used in products currently on the market. This is the first drug developed within own R&D program of NovaMedica. It is planned that it will be available to patients already in 2019.
07 March 2018
Russian pharmaceutical company NovaMedica (investment project of Rusnano), Ministry of Industry and Trade of the Russian Federation and Government of the Kaluga Region have concluded Special Investment Contract (SPIC). Denis Manturov, Minister of the Ministry of Industry and Trade, Anatoly Artamonov, Governor of the Kaluga Region, and Alexander Kuzin, General Director of NovaMedica, signed the contract. Arkady Dvorkovich, Deputy Chairman of the Government of the Russian Federation, and Anatoly Chubais, Chairman of the Executive Board of Managing Company “RUSNANO”, were present during the ceremony. SPIC envisages creation of a greenfield facility for manufacturing of sterile injectable dosage forms in the Kaluga region. During its implementation NovaMedica will invest more than three billion Rubles in the creation of the facility. Today this SPIC is the biggest one in the Russian pharmaceutical industry in terms of the amount of investments.
07 February 2018
Russian pharmaceutical company NovaMedica (investment project of Rusnano) announces start of its cooperation in the area of transfer of knowledge and technologies between the R&D Center of NovaMedica Innotech and the German company Evonik – one of the leading companies in the international market of excipients manufacturing for the pharmaceutical industry. This partnership will result into creation of a training facility for transfer of competences in the area of pharmaceutical technologies at the premises of NovaMedica Innotech in Russia.
26 December 2017
Russian pharmaceutical company NovaMedica, investment project of Rusnano, informed about receipt of conclusion of the Ministry of Industry and Trade of the Russian Federation over compliance of the facility of the R&D Center of NovaMedica Innotech (subsidiary of NovaMedica) with the Russian standards of the Good Manufacturing Practice (GMP). The certificate issued basing on the integrated audit of the MIT RF commission, proves that the processes of development, manufacturing and quality control at NovaMedica Innotech are organized in accordance with the high standards of quality and manufacturing of tablets, soft and hard gelatin capsules and pellets at its manufacturing facilities meet the Russian GMP requirements.
22 December 2017
Russian pharmaceutical company NovaMedica (investment project of Rusnano) informed that it received approval of the Interdepartmental Committee (IDC) to conclude the Special Investment Contract (SPIC) within the investment project devoted to creation of a pharmaceutical plant for manufacturing of sterile injectable drug products in the Kaluga region. This is the first SPIC in the industry which is aimed at support of creation of a greenfield pharmaceutical facility.
02 November 2017
Yulia Sobakina, who used to head Department of private label brands in the pharmacy chain Rigla of the Protek Group of Companies, has been appointed as Commerce & Marketing Vice President of the pharmaceutical company NovaMedica.
11 August 2017
Rustam Iksanov, who used to hold one of the managerial positions in Valenta Pharma, has been appointed as R&D Vice President of pharmaceutical company NovaMedica.
30 May 2017
Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.
29 May 2017
Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the appointment of Alexander Kuzin to the post of General Director (CEO). This decision has taken unanimously by the Board of Directors of NovaMedica on May 26, 2017.
21 April 2017
NovaMedica, Russian pharmaceutical company, and Pfizer, one of the leaders of the world biopharmaceutical industry, were recognized as winners of the open professional contest “Platinum Ounce” in the nomination “Deal of the Year” for the long-term partnership agreement which envisages construction of a high-technology pharmaceutical production facility and localization of more than 30 life-saving and essential drugs in Russia.
17 August 2018
17 August 2018
17 August 2018
16 August 2018